| First Author | Takeda Y | Year | 2018 |
| Journal | Biochem Biophys Res Commun | Volume | 506 |
| Issue | 4 | Pages | 1019-1025 |
| PubMed ID | 30404733 | Mgi Jnum | J:272260 |
| Mgi Id | MGI:6280218 | Doi | 10.1016/j.bbrc.2018.10.166 |
| Citation | Takeda Y, et al. (2018) Vaccine adjuvant ARNAX promotes mucosal IgA production in influenza HA vaccination. Biochem Biophys Res Commun 506(4):1019-1025 |
| abstractText | Adjuvant stimulates pattern-recognition receptors (PRRs) expressed by dendritic cells, which causes immune-enhancing of T lymphocytes. Adjuvant also induces innate immune response in whole-body cells via PRRs to evoke cytokinemia. A cytokine-mediated immune response is important for the systemic protection of a host from microbial infections. Using an influenza subcomponent vaccine in a mouse model, we intranasally administered a TLR3-specific adjuvant ARNAX + HA split vaccine to mice. ARNAX efficiently induced mucosal IgA and systemic IgG production by nasal drop. Moreover, ARNAX + HA simultaneously induced CD8 and CD4 T cell activation. We have previously shown that ARNAX does not induce harmful systemic cytokine production. Thus, our findings indicate that the ARNAX + HA vaccine is a harmless prophylactic vaccine for flu that induces HA-specific T cell activation and IgA/IgG production. These results suggested that ARNAX + antigen enhanced the immune response without inducing inflammatory toxicity for vaccination against infectious diseases. |
